Cellectar Biosciences (NASDAQ:CLRB) Posts Earnings Results, Beats Expectations By $0.66 EPS

Cellectar Biosciences (NASDAQ:CLRB) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.66, Zacks reports.

Here are the key takeaways from Cellectar Biosciences’ conference call:

• Company plans a conditional marketing authorisation (CMA) submission in Europe in Q3 2026 for Iopofosine I‑131 following EMA SAWP guidance, targeting potential approval and commercialization as early as 2027.
• Cellectar says it will pursue an Accelerated Approval pathway in the U.S. (FDA Breakthrough designation) and intends to submit an NDA about 1–2 months after initiating the confirmatory Phase III in the 2nd‑line post‑BTKi setting, with a targeted six‑month review window.
• The company reports that full 12‑month CLOVER‑WaM follow‑up strengthens response durability, PFS and subgroup signals versus prior cuts, and believes moving to an earlier (2nd‑line) setting materially increases the addressable U.S. population.
• Pipeline advancement includes initiation of the CLR‑125 Phase 1b dose‑finding study in triple‑negative breast cancer (two sites active, more to come) with early interim safety, dosimetry and preliminary efficacy data expected mid‑2026.
• Financial runway is limited—cash and equivalents were $13.2M at year‑end 2025 (company says adequate into Q3 2026), and initiation of the CLR‑225 alpha program’s Phase 1 is contingent on additional funding despite completed IND‑enabling work and supply agreements.

Cellectar Biosciences Stock Down 1.7%

Cellectar Biosciences stock traded down $0.05 during mid-day trading on Thursday, hitting $2.85. The company’s stock had a trading volume of 13,436 shares, compared to its average volume of 73,926. Cellectar Biosciences has a 52-week low of $2.45 and a 52-week high of $20.60. The company has a market cap of $12.08 million, a PE ratio of -0.31 and a beta of 0.31. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.77 and a quick ratio of 2.77. The firm’s 50 day moving average is $3.27 and its 200 day moving average is $3.87.

Institutional Trading of Cellectar Biosciences

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Cellectar Biosciences in the 4th quarter valued at approximately $36,000. Bank of America Corp DE grew its holdings in shares of Cellectar Biosciences by 25.3% during the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 41,704 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Cellectar Biosciences in the third quarter worth $73,000. Geode Capital Management LLC raised its holdings in shares of Cellectar Biosciences by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 3,744 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Cellectar Biosciences during the third quarter valued at $104,000. 16.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cellectar Biosciences presently has a consensus rating of “Hold”.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.